PharmAI – Industry Is Smartening Up To Potential Of Artificial Intelligence
Exploring Pharma Deal-Making For AI And Machine Learning Technologies
Executive Summary
AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.
You may also be interested in...
The Bigger Picture And Global Innovation Hotspots
Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally.
Pharma R&D’s COVID-19 Scar
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
Pipeline-In-A-Pill: Still A Winning Strategy?
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
Need a specific report? 1000+ reports available
Buy Reports